Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :734
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed312    
    Printed0    
    Emailed0    
    PDF Downloaded37    
    Comments [Add]    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2022  |  Volume : 59  |  Issue : 5  |  Page : 130-141

Management of human epidermal growth factor receptor 2–negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors


1 Department of Medical Oncology, Medanta - The Medicity, Gurugram, Haryana, India
2 Department of Medical Oncology, Dinanath Mangeshkar Hospital, Pune, Maharashtra, India
3 Department of Medical Oncology, Max Superspeciality Hospital, Saket, New Delhi, India
4 Department of Medical Oncology, TMC, Kolkata, West Bengal, India

Correspondence Address:
Ashok Kumar Vaid
Department of Medical Oncology, Medanta - The Medicity, Gurugram, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_30_21

Rights and Permissions

Human epidermal growth factor receptor 2 (HER2)-negative subset is the most heterogeneous group of metastatic breast cancers (MBCs) as it includes both hormone receptor (HR)-positive and HR-negative breast cancer (or TNBC), which have different therapies and treatment challenges. Though endocrine therapy (ET) remains the treatment backbone in HR-positive HER2-negative cases, about 40% of the patients show intrinsic or acquired resistance to ET due to multiple mechanisms. Combining different therapies such as ET and other targeted therapies with or without chemotherapy fails to give continued benefit, unlike cyclin-dependent kinase (CDK) 4/6 inhibitors that have shown a great benefit. TNBC has conventionally been treated ineffectively with systemic chemotherapy. Recently, poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged for HER2-negative breast cancer (BC) patients, including TNBC. Olaparib and talazoparib have recently been approved in germline BRCA-mutated (gBRCAm) HER2-negative MBC. Additionally, ongoing trials of PARPi in combination with various therapies are expected to provide more and better treatment options for gBRCAm HER2-negative breast cancer.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow